All In Biotech

Drug Trial Radar · NCT07005752

A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

Multi-center, Randomized, Double-blind, Active Controlled, Parallel Clinical Trial for the Evaluation of the Efficacy and Safety of CnU Cap. 750 mg in Patients With Cholesterol Gallstone

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 484 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

484

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Nov 10, 2027

Study completion Jun 13, 2028

Sponsor

Lead sponsor
Myungmoon Pharma. Co. Ltd.Industry
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 750 mg administration in patients with Cholesterol gallstone (radiolucent gallstones)

Conditions

  • Cholesterol Cholelithiasis

Interventions

  • CnU cap. 250mg & Ursa placebo tab. 200mgDrug

    CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

  • Ursa tab. 200mg & CnU placebo cap. 250mgDrug

    Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response to dissolution therapyTime frame: From baseline to the end of treatment at 24 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Kyungpook National University Hospital

    Daegu, South Korea · Recruiting

  • CHA Bundang Medical Center

    Gyeonggi-do, South Korea · Recruiting

  • Hallym University Dongtan Sacred Heart Hospital

    Gyeonggi-do, South Korea · Recruiting

  • Soonchunhyang University Cheonan Hospital

    Gyeonggi-do, South Korea · Recruiting

  • Inha University Hospital

    Incheon, South Korea · Recruiting

  • Inje University Sanggye Paik Hospital

    Seoul, South Korea · Recruiting

  • Kangbuk Samsung Hospital

    Seoul, South Korea · Recruiting

  • Eunpyeong St. Mary's Hospital, The Catholic University of Korea

    Seoul, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Korea University Ansan Hospital

    Ansan, Gyeonggi-do, South Korea · Recruiting

  • Soonchunhyang University Bucheon Hospital

    Bucheon-si, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.